Quantum-Si Incorporated (QSI) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 35.29%. A quarter ago, it was expected that this company would post a loss of $0.18 per share when it actually produced a loss of $0.18, delivering no surprise.Over the last four quarters, the company has surpassed ...

Quantum-Si (QSI) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Company Participants Katherine Atkinson - SVP - Commercial MarketsJeff Hawkins - President & CEOJeff Keyes - CFO Conference Call Participants Kyle Mikson - Managing Director & Senior Research AnalystScott Henry - Managing Director & Senior Research AnalystSwayampakula Ramakanth - Managing Director & Senior Equity Analyst Operator Day, and thank you for standing by. Welcome to the Quantum SI First Quarter twenty twenty five Earnings Call. At thi ...

Quantum-Si (QSI) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Speaker0 Day, and thank you for standing by. Welcome to the Quantum SI First Quarter twenty twenty five Earnings Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there'll be a question and answer session. To ask a question during the session, you'll need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To answer your question, please press 11 ag ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to _________ Commission File Number: 001-39486 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) _______________________ ...

Exhibit 99.1 Quantum-Si Reports First Quarter 2025 Financial Results Launches and Delivers First Platinum Pro Units Announces New Library Preparation Development Program ® BRANFORD, Conn. -- (BUSINESS WIRE) -- May 15, 2025 -- Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum- Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced financial results for the first quarter ended March 31, 2025. Press Release Highlights "We completed a productive quarter, including launching Platinum Pro, c ...

Financial Data and Key Metrics Changes - Total revenues for Q4 2024 were approximately $1.2 million, representing a 52% increase over Q3 2024 and a 183% increase year-over-year [11][35] - Full year 2024 revenues reached $3.1 million, with a gross profit of $1.6 million and a gross margin of 52% [37][38] - Gross profit for Q4 2024 was $610,000, with a gross margin of 51% [35][36] Business Line Data and Key Metrics Changes - The company achieved its first quarter exceeding $1 million in revenue, driven by the commercialization of the Platinum instrument [10] - The customer base diversified significantly, now including academic, biotech, pharma, government, and contract research organizations [10][11] - The company sold its fiftieth Platinum instrument in Q4 2024, marking a significant milestone [12] Market Data and Key Metrics Changes - The company established an international distribution channel with eighteen partners, expanding its market presence in Western Europe, Eastern Europe, Asia, the Middle East, Africa, South America, and the South Pacific [14] - The company noted a growing interest in proteomics research in regions where traditional instruments are cost-prohibitive, positioning its low-cost Platinum technology as an accessible option [15] Company Strategy and Development Direction - The company aims to accelerate commercial adoption, deliver on its innovation roadmap, and preserve financial strength [9] - Plans for 2025 include launching a version four sequencing kit and continuing to develop the Proteus platform, expected to launch in the second half of 2026 [24][30] - The establishment of a scientific advisory board to enhance collaboration and expand the utility of next-generation protein sequencing [21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the international market opportunities and the potential impact of the Avantor partnership, expecting contributions to revenue in the second half of 2025 [44][59] - There is uncertainty regarding NIH funding for 2025, which may affect the academic research market, but other segments like pharma and biotech are expected to remain stable [45][46] - The company anticipates Q1 2025 revenue to be at least $900,000, reflecting a 100% year-over-year growth [46] Other Important Information - The company raised capital through its at-the-market facility, providing an extended cash runway into the second half of 2027 [43] - Adjusted operating expenses for 2025 are projected to be $103 million or less, with total estimated cash usage of $95 million or less [47] Q&A Session Summary Question: Did you sell any Platinum Pro systems since the announcement? - Management confirmed that they expect to start shipping the Platinum Pro before the end of the quarter and have not seen any impact on Platinum sales yet [50][51] Question: Was any of the $1.2 million in Q4 pushed from Q3 or pulled forward from Q1 2025? - Management stated that nothing was pushed from Q3, but some end-of-year buying decisions occurred in Q4 [52][53][54] Question: What are the expectations for the Avantor partnership this year? - Management indicated that Q1 is focused on training and implementation, with expected contributions from the partnership in Q2 and more acceleration in the second half of the year [55][59] Question: Are you seeing a more predictable cadence to sales cycles? - Management acknowledged that the sales cycle is longer than historically seen but is now more consistent [83][84] Question: What is the largest market opportunity and any untapped markets? - Management noted a 50-50 split between academic and other segments, with significant international opportunities identified as untapped markets [86][88][90] Question: Have you expanded your internal commercial team? - Management confirmed that the commercial team is staffed as expected, with some new hires still in training, and they anticipate seeing impacts in the back half of 2025 [93][99]

Quantum-Si incorporated (NASDAQ:QSI) Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ET Company Participants Katherine Atkins - SVP, Commercial Markets Jeff Hawkins - President and CEO Jeff Keyes - CFO Conference Call Participants Kyle Mikson - Canaccord Genuity Douglas Mcpherson - H.C. Wainright Operator Thank you for standing by, and welcome to Quantum-Si's Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in listen-only mode. After the speakers' presentation, there w ...

Group 1: Financial Performance - Quantum-Si Incorporated reported a quarterly loss of $0.18 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.16 per share a year ago [1] - The company posted revenues of $1.19 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 20%, and this is an increase from revenues of $0.4 million a year ago [2] - The current consensus EPS estimate for the upcoming quarter is -$0.18 on revenues of $1.8 million, and for the current fiscal year, it is -$0.75 on revenues of $9.31 million [7] Group 2: Market Performance - Quantum-Si Incorporated shares have declined approximately 48.9% since the beginning of the year, while the S&P 500 has gained 1.2% [3] - The company has surpassed consensus EPS estimates three times over the last four quarters, but has only topped consensus revenue estimates once in the same period [2][1] Group 3: Industry Outlook - The Electronics - Semiconductors industry, to which Quantum-Si belongs, is currently ranked in the bottom 46% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Quantum-Si's stock performance [5] Group 4: Future Expectations - The sustainability of Quantum-Si's stock price movement will largely depend on management's commentary during the earnings call and the outlook for future earnings [3][4] - The current estimate revisions trend for Quantum-Si is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6]

Financial Performance - Quantum-Si incurred net losses of $101.0 million, $96.0 million, and $132.4 million for the years ended December 31, 2024, 2023, and 2022, respectively, with an accumulated deficit of $596.6 million as of December 31, 2024[125]. - The company generated limited product revenue since the controlled launch of its first product, Platinum for RUO, in December 2022, and may never generate sufficient revenue to offset expenses[125]. - As of December 31, 2024, Quantum-Si had cash and cash equivalents totaling $209.6 million, expected to fund operations for at least the next twelve months[131]. - The company has recorded a full valuation allowance related to its NOLs and other deferred tax assets due to uncertainty regarding the realization of future benefits[200]. - As of December 31, 2024, the company had federal net operating loss carryforwards (NOLs) of approximately $388.3 million, with $65.5 million set to expire in 2033 if not utilized[199]. Market and Commercialization Risks - The commercialization plan for Platinum includes three phases: early access limited release, controlled commercial launch, and broad commercial availability, but progress may not occur as planned[135]. - The market for proteomics and genomics technologies is evolving, making it difficult to predict the size of the markets for current and future products[141]. - The success of Quantum-Si's products depends on broad scientific and market acceptance, which may take longer than anticipated, leading to continued operating losses[137]. - The total addressable market estimates for Quantum-Si's products may be incorrect, impacting the company's ability to successfully sell its products[143]. - The company anticipates that a significant portion of its revenue will depend on research and development spending by academic institutions, which is influenced by external budgetary constraints[162]. Operational Challenges - The company faces risks related to unforeseen expenses and challenges as it transitions from a research-focused entity to one capable of supporting commercial activities[127]. - The company may need to raise additional capital to fund ongoing research, development, and commercialization activities, which could adversely affect stockholder rights[133]. - The company experienced a workforce reduction of approximately 12%, 16%, and 23% in January and August 2023, and November 2024, respectively, as part of organizational restructurings aimed at decreasing costs[155]. - The company must navigate the complexities of recruiting and retaining qualified personnel, particularly in a competitive market for scientific and technical talent[158]. - The company faces potential additional costs and delays if it needs to switch contract manufacturers for its products, which could adversely affect its business[167]. Supply Chain and Manufacturing Risks - The company relies on contract manufacturers for its instruments and consumables, and any failure or unsatisfactory performance from these manufacturers could adversely affect commercialization efforts[165]. - The company relies on a limited number of suppliers for certain components, and losing a supplier could disrupt its ability to deliver products, impacting financial results[168]. - The company’s internal manufacturing equipment is specialized, and any failure could significantly hinder semiconductor chip production[169]. - The company relies on third-party foundries for silicon wafer production, and any failure in these partnerships could disrupt semiconductor chip supply[182]. Regulatory and Compliance Risks - The company is subject to various regulatory and operational risks when commercializing products internationally, which could impact financial results[175]. - The FDA's proposed rule to regulate Laboratory-Developed Tests (LDTs) could disrupt the industry and impact the company's sales and business model[221]. - Legislative efforts, such as the VALID Act, aim to create a new category for in vitro clinical tests, which may affect how the company markets its products[221]. - The company must comply with increasingly rigorous data privacy and security regulations, which could impact its operations and revenue[231]. - The company is currently evaluating its compliance obligations related to data protection laws and does not have formal policies in place for data storage, collection, and processing[235]. Intellectual Property Risks - The company relies on patent protection for its products, but uncertainties in patent laws may adversely affect its competitive position[240]. - The patent application process is costly and time-consuming, and failure to secure patents could expose the company to increased competition[242]. - The company may face claims regarding the inventorship of patents, which could lead to costly litigation and loss of valuable intellectual property rights[261]. - The company may incur substantial costs and distractions from defending against claims of wrongful use or disclosure of trade secrets by employees or contractors[264]. - The company may face significant costs and resource diversion due to potential intellectual property litigation, which could adversely affect its business and financial condition[271]. Cybersecurity Risks - Cybersecurity incidents pose a significant risk to the company's operations, potentially leading to financial, legal, and reputational harm[206]. - The company may face significant costs related to protecting against and responding to cybersecurity incidents, which could impact its financial condition[209]. - The company has implemented significant resources to maintain a secure information infrastructure, focusing on cybersecurity as a key element of risk management[310]. - The company has experienced a ransomware incident in August 2020 but did not pay the ransom due to sufficient data backups, leading to enhanced security measures[315]. - The Chief Financial Officer will provide quarterly updates to the Audit Committee on cyber risk topics, including incident response and material threats[317]. Governance and Control Risks - The company may face material weaknesses in internal control over financial reporting, which could adversely affect investor confidence and the accuracy of financial reporting[291]. - The dual class structure of the company's common stock concentrates voting power with Dr. Rothberg, potentially limiting other shareholders' ability to influence important transactions[303]. - The company has a risk of litigation related to restatements and material weaknesses in financial reporting, which could adversely affect its business and financial condition[295]. - The Board of Directors oversees risk management activities, including cybersecurity threats, with the Audit Committee specifically tasked with this oversight[316].

Financial Performance - The company reported revenue of $1.2 million for Q4 2024, with a full year revenue of $3.1 million, representing a 183% year-over-year growth[6] - Total revenue for Q4 2024 was $1,192 million, a significant increase from $400 million in Q4 2023, representing a growth of 198% year-over-year[19] - Product revenue reached $1,149 million in Q4 2024, compared to $377 million in Q4 2023, marking a 205% increase[19] - A net loss of $33.1 million was recorded in Q4 2024, compared to a net loss of $22.0 million in the same period of the prior year[8] - Net loss for Q4 2024 was $33,121 million, compared to a net loss of $22,048 million in Q4 2023, indicating a deterioration in financial performance[21] - Comprehensive loss for Q4 2024 was $33,229 million, compared to $22,048 million in Q4 2023, indicating an increase in overall losses[19] Operating Expenses - Total operating expenses for Q4 2024 were $31.3 million, compared to $28.1 million in the same period of the prior year[6] - Total operating expenses for Q4 2024 were $31,287 million, up from $28,061 million in Q4 2023, reflecting an increase of 8.0%[21] - Research and development expenses for the year 2024 totaled $59,641 million, down from $67,025 million in 2023, a decrease of 11%[19] - Selling, general and administrative expenses for the year 2024 were $50,535 million, compared to $44,634 million in 2023, an increase of 13.5%[19] Profitability Metrics - Gross profit for Q4 2024 was $0.6 million, resulting in a gross margin of 51%, while the full year gross margin was 52%[5] - The company reported a gross profit of $610 million for Q4 2024, up from $178 million in Q4 2023, representing a growth of 242%[19] - Adjusted EBITDA for Q4 2024 was negative $25.1 million, consistent with the same period in the prior year[8] - Adjusted EBITDA for Q4 2024 was $(25,143) million, slightly worse than $(25,078) million in Q4 2023[21] Capital and Cash Position - The company raised over $86 million in capital between Q4 2024 and the first week of 2025, extending its cash runway into the second half of 2027[6] - As of December 31, 2024, the company's cash and cash equivalents and investments in marketable securities totaled $209.6 million[9] Product Development and Launches - The company announced the launch of the Platinum Pro instrument in January 2025, with shipping expected to commence in Q1 2025[6] - The company plans to launch a new version 4 Sequencing Kit in Q3 2025[6] - The company has a strong pipeline of scientific data expected to be released throughout 2025, aimed at maximizing customer adoption[4] Shareholder Metrics - The weighted-average shares used to compute net loss per share for Q4 2024 were 146,329 thousand, compared to 141,575 thousand in Q4 2023[19]